Literature DB >> 15650004

Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium.

A Boulos1, J M Rolain, M N Mallet, D Raoult.   

Abstract

OBJECTIVES AND METHODS: Whipple's disease is a rare multisystem chronic infection, involving the intestinal tract as well as various other organs. Tropheryma whipplei is a slow-growing facultative intracellular bacterium that remains poorly understood. In vitro antibiotic susceptibility testing has previously been assessed in cells using a real-time quantitative PCR assay. In this study, we have evaluated the antibiotic susceptibility of three strains of T. whipplei grown in axenic medium using the same assay.
RESULTS: The active compounds in axenic medium were doxycycline, macrolide compounds, penicillin G, streptomycin, rifampicin, chloramphenicol, thiamphenicol, teicoplanin, vancomycin, amoxicillin, gentamicin, aztreonam, levofloxacin and ceftriaxone, with MICs in the range 0.06-1 mg/L. Cefalothin was less active, with MICs in the range 2-4 mg/L. We found that co-trimoxazole was active with MICs in the range 0.5-1 mg/L, and sulfamethoxazole alone was active with MICs in the range 0.5-1 mg/L. MICs of trimethoprim varied from 64-128 mg/L.
CONCLUSIONS: Co-trimoxazole was effective in vitro, but this activity was due to sulfamethoxazole alone. These results were in accordance with the fact that T. whipplei does not contain the encoding gene for dihydrofolate reductase, the target for trimethoprim.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650004     DOI: 10.1093/jac/dkh524

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Global transcriptome analysis of Tropheryma whipplei in response to temperature stresses.

Authors:  Nicolas Crapoulet; Pascal Barbry; Didier Raoult; Patricia Renesto
Journal:  J Bacteriol       Date:  2006-07       Impact factor: 3.490

Review 2.  Current and past strategies for bacterial culture in clinical microbiology.

Authors:  Jean-Christophe Lagier; Sophie Edouard; Isabelle Pagnier; Oleg Mediannikov; Michel Drancourt; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 3.  [Tropheryma whipplei infection. Colonization, self-limiting infection and Whipple's disease].

Authors:  V Moos; C Loddenkemper; T Schneider
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

Review 4.  Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections.

Authors:  Ruben A V Dolmans; C H Edwin Boel; Miangela M Lacle; Johannes G Kusters
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

Review 5.  Changing paradigms in Whipple's disease and infection with Tropheryma whipplei.

Authors:  V Moos; T Schneider
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-02       Impact factor: 3.267

6.  In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis.

Authors:  Sushim Kumar Gupta; Michel Drancourt; Jean-Marc Rolain
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

7.  Prosthetic hip infection caused by Tropheryma whipplei.

Authors:  Julie Cremniter; Thomas Bauer; Alain Lortat-Jacob; Dominique Vodovar; Jean-Marie Le Parc; Jean-François Emile; Brigitte Franc; Pierre Sebbag; Jean-Louis Gaillard; Beate Heym
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

8.  Fourteen years of severe arthralgia in a man without gastrointestinal symptoms: atypical Whipple's disease.

Authors:  Fabiola Mancini; Serena Sbaragli; Gilberto Colivicchi; Antonio Cassone; Alessandra Ciervo
Journal:  J Clin Microbiol       Date:  2008-12-17       Impact factor: 5.948

9.  Tropheryma whipplei infection.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

10.  Whipple's Disease: Our Own Experience and Review of the Literature.

Authors:  Jan Bureš; Marcela Kopáčová; Tomáš Douda; Jolana Bártová; Jan Tomš; Stanislav Rejchrt; Ilja Tachecí
Journal:  Gastroenterol Res Pract       Date:  2013-06-17       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.